Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Endocrine therapy, Chemotherapy Prednisone.
- Who it may be relevant to
- Registry conditions: ESR1 Gene Mutation, Advanced Breast Cancer. Basic parameters: from 18 years · Female.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Effectiveness and Safety of Different Treatment Regimens in Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer After Failure of Prior Endocrine Therapy: a Prospective, Non-interventional, Real-world Study
Overview
This is a prospective, non-interventional real-world study to observe the efficacy and safety of different treatment regimens in patients with ESR1-mutated HR+/HER2-advanced breast cancer after failure of endocrine therapy. Epidemiological data, efficacy and safety measures will be collected for each subject. Data on efficacy and safety assessment indicators will be collected every 2-3 months until disease progression, receipt of a new anti-tumour treatment modality, death, loss to follow-up, and arrival at the data collection cut-off date. The cut-off date for data collection is defined as 8 weeks after completion of 6 visits for each subject, or 4 weeks after treatment discontinuation and subject discontinuation/withdrawal. Subjects receiving a different treatment regimen remained subject to assessment of safety indicators 4 weeks after discontinuation of the original treatment regimen.
Interventions
- Drug Endocrine therapy
All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc. - Drug Chemotherapy Prednisone
All chemotherapy treatment regimens approved for advanced breast cancer
Primary outcome measures
- PFS [Time frame: 18 months]
Secondary outcome measures (3)
- ORR [Time frame: 6 months]
- CBR [Time frame: 6 months]
- DoR [Time frame: 18 months]
Eligibility criteria
Inclusion criteria
- 1\. must have a histologically or cytologically confirmed diagnosis of breast cancer with evidence of locally advanced disease unsuitable for excision or radical radiotherapy, or evidence of metastatic disease unsuitable for radical treatment.
- 2\. female ≥ 18 years of age
- 3\. female subjects must be postmenopausal (meeting any of the following criteria is sufficient) a) Has undergone oophorectomy. b) Age ≥ 60 years. c) 40 years old < age ≤ 60 years old with 1 year of menopause. d) Age <60 years and receiving ovarian suppression therapy.
- 4\. ER-positive and HER2-negative status and ESR1-mutation positive must be confirmed.
- 5\. must have progressed on at least one line of endocrine therapy prior to enrollment, including monotherapy or combination therapy.
- 6\. have normal organ function (as assessed by the investigator).
Exclusion criteria
- 1\. women who are pregnant or breastfeeding
- 2\. known difficulties in tolerating oral medications, or conditions that interfere with the absorption of oral medications or allergies to medications and their excitements
- 3\. other conditions that make enrollment in the study unsuitable, at the discretion of the investigator
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Tianjin Haidafu Internet Hospital — Suzhou
Identifiers
NCT: NCT06548919 · ABC-RWS-02